| Name | Title | Contact Details |
|---|
We are an industry leader in the medical device market with a diverse product range including advanced automatic injection devices for drug delivery and innovative blood sampling products including lancets, lancing devices and safety lancets. Established in 1952 by Ivan Owen and John Mumford, we have almost 70 years of experience with offices, manufacturing sites and distributors located around the globe. Our corporate headquarters are located in Woodstock, Oxford UK. We are dedicated to providing innovative healthcare solutions for the management of a variety of medical conditions. With one of the most advanced global research, design and manufacturing capabilities that delivers innovation successfully to improve quality of life, encourage patient compliance, prevent infection and reduce healthcare costs; making a world of difference to a world of people.
InfraScan, Inc. is a medical device company that focuses on developing, commercializing, and distributing hand-held diagnostic devices for head injury and stroke assessment based on near infrared (NIR) technology. The Infrascanner enables clinicians to detect effectively, conveniently, and accurately intracranial bleeding in patients with head trauma. Intracranial hematomas are an important treatable cause of secondary brain injury in patients with head trauma. Recent statistics from Iraq shows that 30% of all wounded in action have head injuries; of them 40% have brain hematomas. Dr. Britton Chance (University of Pennsylvania) and Dr. Claudia Robertson (Baylor College of Medicine) invented a NIR system for detection of brain Hematomas and tested it successfully in 305 patients in Baylor. An entrepreneurial team formed a company around this technology in Collaboration with Drexel University and won the Wharton Business Plan competition in April 2004 and the second prize at the global business plan competition in Singapore in October 2004. Office of Naval Research funded the company in May 2004. The company also attracted $1.5M in funding from BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania, from Ben Franklin Technology Partners of Southeastern Pennsylvania, and from Philadelphia Industrial Development Corporation. A multicenter clinical study to support an FDA submission started in July 2006, and on February 2008 an application was submitted to the FDA. After 4 years of review, the FDA cleared Infrascanner Model 1000 as a DeNovo medical technology in December 2011. In January 2013 the FDA cleared the 510(k) of Infrascanner Model 2000.
Arbor Surgical Technologies is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Viable Health Group (usa) is a Millbrae, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MedicSight is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.